伴肝转移的Ⅳ期胃癌手术方式的合理选择

目的探讨不同手术方式对伴肝转移的Ⅳ期胃癌患者的临床疗效。方法回顾性分析1993-2004年间102例伴肝转移的Ⅳ期胃癌病例的手术方式,评价不同术式对预后的影响。结果肝转移H1的胃癌病例行姑息切除后半年、1年和2年的生存率分别为69%、44%和6%,与改道手术、开腹探查术者的生存率比较,差异有统计学意义(P=0.009)。肝转移H2的胃癌病例姑息切除术后半年、1年和2年的生存率分别为56%、13%和6%,与改道手术、开腹探查术者的生存率比较,差异无统计学意义(P=0.068)。肝转移H3的胃癌病例行姑息切除半年、1年和2年的生存率分别为25%、13%和0,与改道手术、开腹探查术者的生存率比较,差异无统计学意义(P=0.157)。有或无腹膜转移的病例,其术后生存率比较,差异亦无统计学意义(P=0.132)。结论肝转移H1的胃癌患者,无论伴与不伴腹膜转移,均应尽量行姑息性切除手术。肝转移H2、H3的Ⅳ期胃癌患者行切除性手术无益于预后。     

Application of technetium-99m hexamethylpropylene amine oxime single-photon emission tomography to neurologic prognosis in patients undergoing urgent carotid surgery

In this study we aimed to work out a quantitative prognostic index for preoperative assessment of brain technetium-99m hexamethylpropylene amine oxime (HMPAO) single-photon emission tomography (SPET) in patients referred for urgent carotid endarterectomy due to acute obstructive disease of the internal carotid artery (ICA) and neurological deficit. To this end we compared data from preoperative SPET studies with the postinterventional changes in neurological status in 20 patients (17 males, three females; mean age 53 years, SD 4 years) with acute ischaemic cerebral disorders induced by obstruction of the ICA. Carotid obstruction was diagnosed by ultrasound B-mode study. All patients underwent urgent carotid endarterectomy from the ICA. Patients were divided into two groups in accordance with the results of postoperative follow-up: group A comprised patients with significant (more than 3 points) postoperative improvement in neurological condition as quantified by the Canadian Neurological Scale (11 patients); group B consisted of patients with minimal improvement or deterioration (nine, three of whom died). All patients were studied preoperatively by^99mTc-HMPAO SPET. The volume of nonperfused tissue (VS, cm³) was quantified using the Mountz technique. Hypoperfused volume (V _hypoperf, cm³) in the affected hemisphere was calculated as the total volume of voxels with^99mTc-HMPAO uptake <90% of the contralateral symmetric voxels. Discriminant prognostic function was calculated by discriminant analysis as:PF = 0.072×VS + 29.46×(VS/V _hypoperf). Patients with preoperativePF values <8.20 demonstrated postoperative improvement in neurological status, while the group withPF>8.90 comprised patients who demonstrated minimal improvement or deterioration. PF values in the range 8.20–8.90 carried an indefinite prognosis. We conclude that the preoperative^99mTc-HMPAO SPET can be used for the selection of patients in whom improvement in neurological status may be expected after urgent surgical correction of acute extracranial obstruction of the ICA.     

P-glycoprotein expression in soft-tissue sarcomas

Multidrug resistance (MDR) is an important problem in chemotheraphy for neoplastic disease. In humans, MDR is mainly mediated by P-glycoprotein (P-gp), a product of theMDR1 gene, which acts as a transmembrane protein pump and eliminates chemotherapeutic agents from the cells. Expression of P-gp was immunohistochemically studied by using two monoclonal antibodies, JSB-1 and C-219, on paraffin-embedded sections from 55 patients with soft-tissue sarcoma. The histological diagnosis of tumors was malignant fibrous histiocytoma in 24 cases, liposarcoma in 9, synovial sarcoma in 7, malignant neurogenic tumors in 6, leiomyosarcoma in 5, others in 4. The histological grade was determined on the basis of criteria previously proposed by us. Out of 55 cases, 34 (62%) were positive for P-gp expression. There was a significant difference in P-gp expression between high-grade (90%) and intermediate and low-grade tumors (46%) (P<0.005). Tumors expressing P-gp had a less favorable prognosis than P-gp-negative tumors in the high- and intermediate-grade tumors. The current study demonstrated that the estimation of P-gp expression could be used to select appropriate therapeutic modalities.Abbreviations MDR multidrug resistance - P-gp P-glyco-protein     

Skip mediastinal nodal metastases in non-small cell lung cancer

Objective: To reveal the incidence and clinical significance of mediastinal nodal metastases without N1-station nodal metastases (‘skip-N2 metastases’) in non-small cell lung cancer (NSCLC). Methods: A total of 450 NSCLC patients who underwent tumor resection with a systemic mediastinal nodal dissection were retrospectively reviewed. p53 status and proliferative activity represented as proliferative index (PI) were also examined immunohistochemically. Results: Skip-N2 metastases were documented in 49 (13%) patients of all 450 patients; among 334 patients without N1-nodal involvement, 18% patients had skip-N2 metastases. The postoperative survival of skip-N2 patients was almost same as that for patients with metastases to both N1 and N2 nodes. Skip-N2 metastases were significantly more frequent in male patients and squamous cell carcinoma patients. In addition, the mean PI for tumor with skip-N2 metastases was significantly higher than that for any other pathologic nodal (pN)-status diseases. Combined with histologic type and PI, the incidences of skip-N2 metastases for adenocarcinoma showing lower PI were only 5% (7/137) of all patients and 7% (7/94) of patients without N1-nodal involvement. Conclusions: N1 nodal status is not a useful predictor of N2 nodal status in NSCLC, because skip-N2 metastases were documented in 18% patients showing no N1-nodal involvement. However, N1 node-guided dissection might be performed in patients with adenocarcinoma showing lower PI, because the incidence of skip-N2 metastases was extremely low.     

高龄急性脑梗死患者阿替普酶静脉溶栓有效性、安全性及预后影响因素分析

目的 探讨高龄急性脑梗死患者接受阿替普酶静脉溶栓治疗有效性、安全性和临床预后的影响
因素。
方法 前瞻性连续纳入江苏省苏北人民医院2016年9月-2018年9月收治入院进行阿替普酶静脉溶
栓治疗的急性脑梗死患者，按照年龄将患者分为年龄≥80岁组和年龄＜80岁组。比较两组患者入院
时、溶栓24 h NIHSS评分，6个月mRS评分及死亡率，观察两组溶栓相关出血转化、症状性颅内出血及
肺部感染的发生情况。应用多因素Logistic回归分析观察所有患者静脉溶栓预后的独立影响因素。
结果 最终共纳入患者119例，男性69例（58.0%），年龄范围46～94岁，平均70.12±10.55岁，入院
NIHSS评分4～38分。其中年龄≥80岁患者29例，年龄＜80岁患者90例。静脉溶栓后，两组患者溶栓
24 h NIHSS评分较入院时均明显降低（均P＜0.05），两组治疗24 h NIHSS评分比较差异无统计学意义；
两组的出血转化、症状性颅内出血、肺部感染、6个月预后良好及死亡率比较，差异均无统计学意义。
多因素Logistic回归分析显示，入院到静脉溶栓时间、入院时NIHSS评分及肺部感染是脑梗死静脉溶
栓6个月预后的独立危险因素（P＜0.05），高龄不是影响预后的因素（P＞0.05）。
结论 高龄急性脑梗死患者静脉溶栓治疗安全有效，未增加颅内出血转化风险、死亡率及不良预
后。入院到静脉溶栓时间、入院时NIHSS评分及肺部感染是急性脑梗死患者静脉溶栓6个月预后不良
的独立危险因素。     

原发性肝癌凝血功能变化的临床价值

目的 :探讨原发性肝癌患者凝血功能变化情况及其临床价值。方法 :对原发性肝癌 6 0例进行凝血酶原时间 (PT)、活化部分凝血酶原时间 (APTT)、纤维蛋白原 (FIB)、凝血酶时间 (TT) 4项凝血指标进行检测和对比分析。结果 :原发性肝癌组与对照组相比 ,PT、APTT、TT均显著延长 P<0 .0 1,FIB明显降低 P<0 .0 5 ,肝癌并发症组与无并发症组相比 ,PT、APTT均显著延长 P<0 .0 1,P<0 .0 5 ,FIB显著降低 P<0 .0 1;原发性肝癌转移组与无转移组相比 ,PT、APTT明显延长 P<0 .0 5 ,FIB显著降低 P<0 .0 5。不同肝功能分级检测结果显示 PT、APTT和 FIB有显著差别。结论 :原发性肝癌患者可出现凝血功能障碍 ,而凝血功能变化情况对评估肝癌肝损害的程度、监测病情变化 ,指导临床治疗及其预后具有一定的应用价值。     

多发性骨髓瘤合并肾功能不全38例临床和预后分析

目的研究多发性骨髓瘤合并肾功能不全的临床特点及肾功能可逆性的相关因素和生存相关因素。方法回顾性分析1999-01~2003-12北京协和医院收治的91例初治多发性骨髓瘤及其中38例多发性骨髓瘤合并肾功能不全患者的临床资料。结果91例初治多发性骨髓瘤中有38例(41·8%)合并肾功能不全。合并肾功能不全的患者病程进展更快,贫血更严重,血乳酸脱氢酶(LDH)和β2-微球蛋白(β2-MG)质量浓度更高,以及尿蛋白量更多,同时对化疗的反应更差及生存时间更短。其中34·2%的患者肾功能不全是可逆的,血肌酐和LDH是肾功能可逆的独立预测因素。肾功能可逆患者的生存时间与肾功能正常患者的生存时间比较差异无显著性意义。Cox生存多因素分析发现肾功能可逆性(B=1·294,EXP(B)=3·647,P=0·001)是与生存惟一相关的因素。结论肾功能不全是多发性骨髓瘤常见并发症,相当一部分患者的肾功能可以恢复正常,血肌酐水平和LDH水平是肾功能可逆的重要因素,肾功能可逆性是独立的生存预后因素。     

脑梗死OCSP分型和预后

目的了解脑梗死患者OCSP临床分型的构成及不同亚型与预后及复发的关系。方法采用回顾性队列研究,登记2002年1月~2005年6月第四军医大学西京医院神经内科确诊的617例脑梗死患者,按照OCSP标准分型并进行随访,分析各亚型与预后及复发的关系。结果OCSP各亚型构成比分变为:TACI占7.3%,PACI23.3%,POCI6.0%,LACI63.4%,分型与预后明显相关,TACI的预后最差,POCI和LACI预后相对较好,PACI次之,卒中复发与分型无明显相关。结论OCSP分型作为一种脑梗死临床分型方法,可以为脑梗死的预后判断提供参考依据。